Life Sciences

  • January 30, 2026

    CBD Cos. Say They're Wrong Defendants In Kratom Suit

    Shaman Botanicals LLC and CBD American Shaman LLC are urging a California federal judge to throw out claims that they mislead consumers by failing to warn them that Soma Kratom products are dangerous and addictive, saying they're not affiliated with Soma Kratom in the first place.

  • January 30, 2026

    Dozens Of Cases Linking Zantac To Cancer Thrown Out

    A Delaware state trial judge tossed over 200 cases by individuals alleging Boehringer Ingelheim's discontinued heartburn medication Zantac caused cancer, ruling the claims were time-barred.

  • January 30, 2026

    Drugmakers Ask To Appeal Overarching Conspiracy Claim

    A group of pharmaceutical companies that failed to secure a pretrial win on an overarching conspiracy claim in a sprawling generic-drug antitrust enforcement action is asking a Connecticut federal judge to let them seek Second Circuit review, saying the ruling raises a novel legal issue.

  • January 30, 2026

    ThermoLife Asks Justices To Resolve Split Over Sanctions

    ThermoLife is asking the U.S. Supreme Court to take up its fight against a lower court's decision to sanction the company and its CEO as part of a false advertising case, saying the Federal Circuit wrongly backed the award.

  • January 30, 2026

    Amazon Says Shoppers' Labeling Suit Is Corrupted By AI Errors

    In customers' latest filing in their proposed class action accusing Amazon of failing to make required disclosures on dietary supplement product pages, the e-commerce giant alleges that the plaintiffs have submitted a document riddled with errors derived from the use of generative text.

  • January 30, 2026

    Drug Cos. Want Rethink Of DQ Bid Targeting Ex-Prosecutor  

    More than two dozen pharmaceutical companies accused of fixing generic-drug prices have again asked a Pennsylvania federal judge to disqualify a former Connecticut assistant attorney general now in private practice from representing insurers Humana Inc. and Molina Healthcare Inc. in a sprawling multidistrict litigation proceeding.

  • January 30, 2026

    AstraZeneca Beats FMLA Suit After Ex-Worker Went Silent

    AstraZeneca won't have to face a former employee's lawsuit alleging the pharmaceutical giant fired him for taking medical leave to address his gastrointestinal illness, a Connecticut federal judge ruled, saying he failed to respond to discovery and motions and ignored court orders.

  • January 29, 2026

    J&J, Talc Unit Get Patients' Bankruptcy Fraud Claims Tossed

    A New Jersey federal judge Thursday tossed a proposed class action brought by cancer patients who allege that Johnson & Johnson's maneuvers to settle thousands of tort claims through Chapter 11 involved fraud, saying the plaintiffs have not asserted an injury that confers standing to sue.

  • January 29, 2026

    Conn. Drug Price Cap Survives Distributor Challenge, For Now

    The Second Circuit has declined a bid to immediately block the state of Connecticut from enforcing a cap on generic and off-patent drug prices while the Healthcare Distribution Alliance, a collection of wholesale distributors, challenges the new law.

  • January 29, 2026

    ITC To Review Medical Imaging Imports For Infringement

    The U.S. International Trade Commission said it is looking into medical imaging device imports for alleged patent infringement in response to a complaint from a Canadian-American firm.

  • January 29, 2026

    Teva Tries To Spike Paragard Trial Claims, Punitive Damages

    About a week into its first trial over the alleged dangers of the Paragard contraceptive, Teva Pharmaceuticals asked a Georgia federal judge Wednesday to cut the case short and hand it an early win, or at least let it out of a bid for punitive damages.

  • January 29, 2026

    Inspire Medical Leaders Face Suit Over Apnea Device Rollout

    Brass of Inspire Medical Systems Inc. face shareholder derivative claims they breached their fiduciary duties by concealing issues affecting the launch of the company's latest sleep apnea device, damaging investors after its trading prices fell 32% when the issues were disclosed.

  • January 29, 2026

    Imported Scooters Not Duty-Free, UK Court Says In Reversal

    Mobility scooters imported into the U.K. by two companies should be assessed a 10% duty, a London court ruled, reversing a lower court decision it said labeled the scooters duty-free due to a misapplication of relevant rules.

  • January 29, 2026

    Sandoz, Teva Beat Malicious Prosecution Claims, For Now

    Sandoz and Teva have won a reprieve from a former pharmaceutical marketing executive claiming the drugmakers and their officers offered him up to federal prosecutors with fabricated assertions of price-fixing, with a New York federal judge concluding the suit "does not come close" to the standard for malicious prosecution.

  • January 29, 2026

    Dispensaries Sue Hawaii Over Criminalizing Hemp Products

    Two dispensary owners are suing Hawaii's attorney general and the Hawaii State Department of Health, alleging that the state's new law regulating hemp products is preempted by the 2018 Farm Bill and violates the supremacy clause by criminalizing conduct Congress legalized.

  • January 29, 2026

    SpaceX Eyes IPO At $1.5 Trillion Value, Plus More Rumors

    Elon Musk's SpaceX is preparing plans to launch an initial public offering that would value it at a massive $1.5 trillion, Chevron is seeking better terms from Iraq before buying Russia's Lukoil assets, and cryptocurrency wallet Ledger is weighing a $4 billion U.S. IPO.

  • January 28, 2026

    Trade Secret Filings Hit Record High In 2025, Report Finds

    Trade secret litigation reached an all-time high in 2025, with more than 1,500 federal cases filed for the first time ever, according to a new report by legal analytics firm Lex Machina, which also highlights trends about damages, the busiest courts and the law firms most frequently involved.

  • January 28, 2026

    Biogen Can't Escape Amended Antitrust Suit Over MS Drug

    Biogen Inc. must face health plans' claims that it bribed pharmacy benefit managers to stifle generics competition for its multiple sclerosis drug Tecfidera, after an Illinois federal judge found Wednesday that the plans' latest amended complaint in their consolidated antitrust litigation corrects her prior concerns with the pleadings.

  • January 28, 2026

    Teva Allowed New Mifepristone Claim But Not New Defendant

    A California federal judge gave Teva permission to update its antitrust suit accusing Corcept Therapeutics of using patent system abuse, bribes and exclusive dealing to block generic competition to its cortisol disorder treatment while refusing to let Teva add another specialty pharmacy as a defendant.

  • January 28, 2026

    Tax Court Rejects Aventis' Securitizing Debt Assets

    Pharmaceutical giant Aventis Inc. is ineligible for a favorable tax treatment on its securitization of financial assets, the U.S. Tax Court ruled Wednesday, finding the company did not comply with statutory requirements and failed to show it was not the beneficial owner of the assets.

  • January 28, 2026

    After Fed. Circ. Remand, PTAB Again Backs Bausch Patent

    The Patent Trial and Appeal Board has found again that MSN Laboratories failed to show that a drug patent owned by Bausch Health Ireland Ltd. was invalid, after the Federal Circuit told the board to take another look last year.

  • January 28, 2026

    New Squires Order Allows 4 Patent Reviews, Denies 25 Others

    U.S. Patent and Trademark Office Director John Squires instituted four America Invents Act patent challenges while denying 25 others in his most recent summary decision.

  • January 28, 2026

    Attys Get $2.5M In $7.5M Preterm-Birth Drug Settlement

    A New Jersey federal judge has given final approval to a $7.5 million settlement to end claims that AMAG Pharmaceuticals Inc. knew its preterm-birth prevention drug Makena was ineffective when it first marketed it, along with $2.5 million to class counsel in attorney fees.

  • January 28, 2026

    BlackRock, Eclipse Lead Cellares' $257M Funding Round

    Integrated development and manufacturing organization company Cellares, which focuses on the large-scale manufacturing of cell therapies, on Wednesday announced that it closed a $257 million funding round, bringing the South San Francisco, California-based company's total capital raised to $612 million.

  • January 28, 2026

    Crowell & Moring Adds Tech Firm IP Atty In Southern Calif.

    Crowell & Moring LLP is expanding its California team, bringing in an intellectual property attorney most recently with biotechnology firm Grail as a partner in its Orange County office in Irvine.

Expert Analysis

  • Series

    Law School's Missed Lessons: Intentional Career-Building

    Author Photo

    A successful legal career is built through intention: understanding expectations, assessing strengths honestly and proactively seeking opportunities to grow and cultivating relationships that support your development, say Erika Drous and Hillary Mann at Morrison Foerster.

  • Trending At The PTAB: The Policies That Are Redefining IPR

    Author Photo

    The evolution of the Patent Trial and Appeal Board's inter partes review institution regime last year, coupled with the policy considerations behind that evolution, marks a shift toward greater gatekeeping of the U.S. Patent and Trademark Office's resources and patent enforcement rights, say attorneys at Finnegan.

  • 4 Trends Shaping Drug And Medical Device Law For 2026

    Author Photo

    2025 saw some significant legal developments with potential impact for drug and device manufacturers, ranging from growing skepticism in science and regulatory entities to new regulation of artificial intelligence, say attorneys at Faegre Drinker.

  • Trending At The PTAB: The Journey Of IPR Institution In 2025

    Author Photo

    Over the course of 2025, inter partes review institution at the Patent Trial and Appeal Board evolved into a more restrictive, policy-driven regime with reshaped discretionary briefing and assessment, and increasing procedural requirements, say attorneys at Finnegan.

  • A Meaningful Shift In FDA's Biosimilarity Analysis

    Author Photo

    The U.S. Food and Drug Administration's potential pivot away from routinely requiring comparative efficacy studies for interchangeable biosimilar applications would not lower regulatory standards, but instead allow applicants to allocate resources toward establishing more probative evidence, says Theodore Thompson at Stinson.

  • 4 Developments That Defined The 2025 Ethics Landscape

    Author Photo

    The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.

  • Navigating AI In The Legal Industry

    Author Photo

    As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.

  • How Fractional GCs Can Manage Risks Of Engagement

    Author Photo

    As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.

  • 2025 Legal Milestones That Will Shape Psychedelics Sector

    Author Photo

    As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.

  • Series

    Nature Photography Makes Me A Better Lawyer

    Author Photo

    Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.

  • What Defense Teams Must Know About PFAS Testing Methods

    Author Photo

    Whether testing for per- and polyfluoroalkyl substances produces results meaningful for litigation depends on the validity of the sampling methodology — so effectively defending these claims requires understanding the scientific and legal implications of different PFAS testing protocols, say attorneys at Hollingsworth.

  • Series

    Law School's Missed Lessons: Practical Problem Solving

    Author Photo

    Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.

  • Intellectual Property Challenges In AI-Driven Drug Discovery

    Author Photo

    Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.

  • Reel Justice: 'The Mastermind' And Juror Decision-Making

    Author Photo

    The recent art heist film “The Mastermind” forces viewers to discern the protagonist’s ambiguous motives and reconcile contradictions, offering lessons for attorneys about how a well-crafted trial narrative can tap into the psychological phenomena underlying juror decision-making, says Veronica Finkelstein at Wilmington University.

  • Learning From 2025 FCA Trends Targeting PE In Healthcare

    Author Photo

    False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.